Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Eli Lilly shares gain after investigational obesity treatment helps patients lose up to 58 pounds, on average
07:53am, Tuesday, 27'th Jun 2023
Shares of Eli Lilly & Co. LLY, -1.33% gained 1.6% premarket on Tuesday after the company released new data late Monday on its investigational obesity drug retatrutide. The treatment resulted in averag
5 Things to Know Before Markets Open
07:41am, Tuesday, 27'th Jun 2023
EV truck maker Lordstown Motors files for bankruptcy and online brokerage Robinhood cuts 7% of its workforce. Here's what investors need to know today.
New developments in weight-loss drugs: Novo Nordisk, Eli Lilly & Pfizer advance studies
07:40am, Tuesday, 27'th Jun 2023
Dr. Angela Fitch, Knownwell chief medical officer and president of Obesity Medicine Association, joins 'Squawk Box' to discuss the advances in weight-loss drugs, what it means for the obesity epidemic
More evidence needed on Lilly's weight loss drug, UK watchdog says
05:55am, Tuesday, 27'th Jun 2023
UK's drug cost-effectiveness watchdog on Tuesday did not recommend Eli Lilly's weight loss drug for adults with diabetes, saying more evidence was needed before it could be used by the National Health
Eli Lilly stuns doctors as obesity drug sparks 24% weight loss
04:01am, Tuesday, 27'th Jun 2023
A new drug to tackle obesity cut the weight of participants by an average of 58 pounds at the end of its latest clinical trial, US drug giant Eli Lilly announced last night. Results from the trial of
Obesity weight loss market will remain a duopoly between Novo Nordisk and Eli Lilly: BofA'S Meacham
06:49pm, Monday, 26'th Jun 2023
Geoff Meacham, Bank of America Securities, joins 'Fast Money to discuss the state of the weight-loss drug market as Eli Lilly and Novo Nordisk compete for market share.
Eli Lilly experimental obesity drug helped patients lose up to 24% of their weight, study says
06:24pm, Monday, 26'th Jun 2023
By 48 weeks, patients who took Eli Lilly's retatrutide lost 58 pounds on average, the pharmaceutical company said in a mid-stage clinical trial.
Lilly experimental 'triple g' obesity drug leads to 24.2% weight loss in trial -NEJM
05:43pm, Monday, 26'th Jun 2023
Eli Lilly's mid-stage trial of its next-generation "triple g" obesity drug candidate found that the highest dose of the weekly injection to led to weight loss of 24.2% after 48 weeks, the New England
Trial anticipation for weight loss drugs shows they will be popular, says Dr. Kavita Patel
03:30pm, Monday, 26'th Jun 2023
Dr. Kavita Patel, NBC News medical contributor, joins 'Power Lunch' to discuss the anticipation for weight loss drugs.
Weight-loss drugs in development aim to replace injections with pills
03:21pm, Monday, 26'th Jun 2023
Wall Street's obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills i
Experimental Lilly pill leads to 14.7% weight loss in mid-stage trial
05:34pm, Friday, 23'rd Jun 2023
Results from a mid-stage trial found that the highest dose of Eli Lilly's experimental pill orforglipron helped people who were obese or overweight lose 14.7% of their body weight after 36 weeks, the
Lilly (LLY) Gets FDA Nod for Pediatric Use of Diabetes Drugs
02:06pm, Thursday, 22'nd Jun 2023
Following FDA's label expansion approval, Lilly's (LLY) Jardiance and Synjardy are the first SGLT2 inhibitors approved for use in children aged 10 years and older with type 2 diabetes.
More News Is Coming on Lilly, Novo Nordisk's New Weight-Loss Drugs
03:30am, Thursday, 22'nd Jun 2023
At a conference beginning Friday, Eli Lilly and Novo Nordisk will show off next-generation weight-loss drugs. Wall Street—and Hollywood—are already mad for their existing weight-loss products.
FDA approves Eli Lilly and Boehringer Ingelheim's Jardiance for children 10 and older with type 2 diabetes
01:29pm, Wednesday, 21'st Jun 2023
The U.S. Food and Drug Administration has approved the use of Jardiance 10 mg and 25 mg tables to lower blood sugar along with diet and exercise in children aged 10 years and older with type 2 diabete
ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics
01:19pm, Wednesday, 21'st Jun 2023
Eli Lilly (LLY) has agreed to acquire DICE Therapeutics (DICE) in a cash deal worth approximately $2.4 billion. This strategic move is part of Eli Lilly's efforts to bolster its immunology pipeline, s
